Verus Sues AstraZeneca For $1.28B Over Deals To Develop Pediatric Asthma Drug
Verus claims that it is being “destroyed” by AstraZeneca’s move to terminate a high-value pediatric asthma deal.
Verus claims that it is being “destroyed” by AstraZeneca’s move to terminate a high-value pediatric asthma deal.